Can lactoferrin modulate the immunostimulant activity of levamisole in rats immunosuppressed by cyclophosphamide?

Abstract

Objective: The aim of this study was to study the immunomodulatory activity improvement of levamisole by using lactoferrin when applied to immunosuppressed rat model. Methods: The study was designed as follows, 140 male albino rats (250-280 g) 14 weeks old were used in our work. Rats were randomly divided into seven groups, 20 in each. The group I was kept as a control, group II was given cyclophosphamide (CYP) at a single intraperitoneal dose of (250 mg/kg body weight), group III CYP and lactoferrin (Lac) treated group, group IV orally administrated Lac only (0.5%) in drinking water, group V treated with CYP and levamisole, group VI administrated levamisole orally at a dose of (2.5 mg/kg body weight) and group VII was given CYP, Lac and levamisole. Animals were sacrificed and two separate blood samples were collected after 21 days from the beginning of the experiment for measuring the total and differential leukocyte count, serum total proteins, albumin, alpha globulin, beta globulin and gamma globulin, Nitric oxide (NO) production and lysozyme activity. Results: CYP group showed significant decrease in the above mentioned parameters, which were improved after administration of both lactoferrin and levamisole. Conclusion: Our study concluded that lactoferrin improve the immunostimulant effect of levamisole in CYP- immunosuppressed rats. J Clin Exp Invest 2014; 5 (1): 48-53

Keywords

• Bovine lactoferrin (Lac), Levamisole , Cyclophosphamide(CYP), Immunomodulation, Lysozyme assay

Laktoferrin siklofosfamid ile immunsuprese ratlarda levamizol\'un immün stimulan etkisini düzenleyebilir mi?

Abstract

Amaç: Bu çalışmanın amacı immunsuprese rat modelinde laktoferrin kullanılarak levamizolün immün düzenleyici aktivitesini araştırmaktır. Yöntemler: Çalışma planı: Çalışmada 14 haftalık 140 erkek albino rat (250-280 g) kullanıldı. Ratlar herbirinde 20 rat bulunan 7 gruba ayrıldı. Birinci grup Kontrol grubu, Grup II\'ye siklofosfamid tek intraperitoneal dozda (250 mg), Grup III siklofosfamid ve laktoferrin verilen grup, Grup IV oral içme suyu içinde sadece Laktoferrin (%0,5) verilen grup; Grup V siklofosfamid ve levamizol ile tedavi edildi, Grup VI\'ya oral levamizol (2,5 mg/kg) verildi ve GrupVII\'ye laktoferrin, siklofosfamid ve lavamizol verildi. Hayvanlar feda edildi ve çalışmanın başlamasını takib eden 21. Günde iki farklı kan örneği alındı ve total ve ayırıcı lökosit sayısı, serum total proteinleri, albümin, alfa globülin, beta globülin, gama globülin, nitrik oksit üretimi ve lizozim aktivitesi ölçüldü. Bulgular: Siklofosfamid grubunun yukarıda bahsedilen parametrelerinde anlamlı düşüş gözlendi ki bu durum hem laktoferrin hem de levamizol verilmesi ile düzeldi. Sonuç: Bu çalışmamızda siklofosfamid ile immunsuprese edilen ratlarda laktoferrinin levamizolün immunstimulan etkisini iyileştirdiği sonucuna varıldı.

Keywords

• Sığır laktoferrini, Levamizol, Siklofosfamid, Immunmodülasyon, Lizozim deneyi

References

1. Rajasekar T, Usharani J, Sakthivel M, Deivasigamani B. Immunostimulatory effects of Cardiospermum halicacubum against Vibrio parahaemolyticus on ti- ger shrimp Penaeus monodon. J Chem Pharm Res 2011;3:501-513.
2. Mirkes P E. Cyclophosphamide teratogenesis: a re- view. Terat Carcin Mutagen 1985;5:75-88.
3. McCormick S, Dowler K, Armstrong J A and Hsiung G D.Cyclophosphamide immunosuppression during lymphotropic herpes-virus infection in the guinea pig model: A histopathologic and virologic study. Am J Pathol 1987;127:538-548.
4. Jabbar A, Zafar I, Dominique K, et al. Anthelmin- tic resistance: The state of play revisited. Life Sci 2006;79:2413-2431.
5. Farghali H, Masek K. Immunopharmacologic agents in the amelioration of hepatic injuries. Int J immunophar- macol 1998;20: 125-139.
6. Boyer O, Moulder J K, Grandin L, Somers MJG. Short and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome. Pediatr Nephrol 2008;23:575-580.
7. Donia AF, Amer GM, Ahmed HA, et al. Levamisole: ad- junctive therapy in steroid dependent minimal change nephrotic children. Pediatr Nephrol 2002;17:355-358.
8. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J. Lactoferrin structure and functions. Adv Exp Med Biol 2008; 606:163-194.

9. Legrand D, Elass E, Carpentier M, Mazurier J. Lacto- ferrin: a modulator of immune and inflammatory re- sponses. Cell Mol Life Sci 2005; 62:2549-2559.
10. Brock J H. The physiology of lactoferrin. Biochem Cell Biol 2002;80:1-6.
11. Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natu- ral immune modulator. Curr Pharm Des 2009;15:1956- 1973.
12. Viswanatha Swamy AHM, Patel UM, Koti C, et al. Cardioprotective effect of Saraca indica against cy- clophosphamide induced cardiotoxicity in rats: A bio- chemical, electrocardiographic and histopathological study. Indian J Pharmacol 2013;45:44-48.
13. Osama AA, Mohamed EE. Effect of lactoferrin on some selective immunological parameters in rats im- munosuppressed by cyclophosphamide. J Investig Biochem 2013;2:136-140.
14. Shaha D, Londhe V, Mazumder R, Parikh R. Can le- vamisole alone maintain the immunity? International Journal of Pharmacy and Pharmaceutical Sciences 2011;3:161-164.
15. Feldman BF, Zinkl JG, Jain NC (Eds.). Text book of Shalm’s Veterinary Hematology. 5th Ed, Lippincott Wil- iams & Wilkins, Philadelphia 2000.
16. Coles EH (Ed.). In: Textbook of Veterinary Clinical Pathology. 4th Ed, W.B. Saunders Company, Philadel- phia 1986.
17. Henry R J, Cannon D C and Winkelman J W (Eds.). Clinical chemistry, principles and techniques 2nd Ed, Harper & Row, Hagerstown, Maryland, USA 1974.
18. Doumas BT, Bayso DD, Carter RJ, Peters T, Schaffer R. Determination of serum albumin. Clin Chem Acta 1981;27:1642.
19. Parry RM, Chandan RC, Shahani KM. A rapid and sensitive assay of muramidase. Proc Soc Exp Biol Med 1965;119:384-386.
20. Siwicki AK, Anderson DP. Immunostimulation in fish: measuring the effects of stimulants by serological and immunological methods. US Fish Wildlife Service, IFI, Olsztyn1993;1:17.
21. Keller R, Keisi R, Wechsler A, et al. Mechanisms of macrophage-mediated tumor cell killing: A compara- tive analysis of the roles of reactive nitrogen inter- mediates and tumor necrosis factor. Int J Cancer 1990;466-482.
22. Angulo FGH, J F Garcia-Bustos JF, Gargallo D, Mu- noz-Fernandez MA, Fresno M. Nitric oxide-producing D11b+Ly-6G(Gr-1)+CD31(ER-MP12)+ cells in the spleen of cyclophosphamide-treated mice: implica- tions for T-cell responses in immunosuppressed mice. Blood 2000;95:212-220.
23. Duncan D B. Multiple ranges and multiple F-test. Bio- metrics1995;11:1-42.
24. Brock N. Oxazaphosphorine cytostatics: past-present- future: seventh Cain Memorial Award lecture. Cancer Res 1989;49:1-7.
25. Winkelstein A. Mechanisms of immunosuppression: effects of cyclophosphamide on cellular immunity. Blood 1973;41:273-284.
26. Jolanta A, Michal Z, Marian LK. Enhanced clearance of Escherichia coli and Staphylococcus aureus in mice treated with cyclophosphamide and lactoferrin. Int Immunopharmacol 2004;4:1149-1157.
27. Swierczewska E, Niemiec J, Glowacka JN. A note on the effect of immunostimulation of laying hens on the lysozyme activity in egg white. Animal Sci Paper Re- ports 2003;21:63-68.
28. Khaksary M M, Ranjbar R, Arzi A, et al .Comparison study of effects of Echinacea extract and levamisole on phenytoininduced cleft palate in mice. Regul Toxi- col Pharmacol 2006;46:163-166.
29. Holcombe R F , McLaren C E, Milovanovic T .Immuno- modulation with low dose levamisole in patients with colonic polyps. Cancer Detect Prevent 2006;30:94-98.
30. Mohri M, Seifi HA, Zamani Sani SH. Effects of oral administration of levamisole on non-specific immu- nity, serum proteins and health in normal colostrum- fed neonatal dairy calves. Compartive Clin Pathol 2005;13:132-136.
31. Saeed S E, Hadi k N, Narges A, et al. Synergetic ef- fects of oral administration of levamisole and Echina- cea purpurea on immune response in Wistar rat. Res Vet Sci 2011;91:82-85.
32. Senthilkumar S, Devaki T, Manohar BM, Babu MS. Effect of squalene on cyclophosphamide-induced tox- icity. Clin Chim Acta 2006 ;364:335-342.
33. King PD, Perry M. Hepatoxicity of chemotherapy. On- cologist 2001;6:162-176.
34. Zhao R, Ma C, Tan L, Zhao X, Zhuang D. The effect of acupuncture on the function of macrophages in rats of immunodepression. Zhen Ci Yan Jiu 1994;19:66-68.
35. Hickmann-Davis JM, Lindsey JR, Matalon S. Cy- clophosphamide decreases nitrotyrosine forma- tion and inhibits nitric oxide production by alveo- lar macrophages in mycoplasmosis. Infect Immun 2001;69:6401-6410.
36. Choe Y, Lee S. Effect of lactoferrin on the production of tumor necrosis factor α and nitric oxide. J Cell Bio- chem 1999;76:30-36.
37. Crouch SPM, Slater KJ, Fletcher J. Regulation of cytokine release from mononuclear cells by the iron- binding protein lactoferrin. Blood 1992;80:235-240.
38. Shinoda I, Takase M, Fukuwatari Y, et al. Effects of lactoferrin and lactoferricin on the release of inter- leukin 8 from human polymorphonuclear leukocytes. Biosci Biotechnol Biochem 1996;60:521-523.
39. Sorimachi K, Akimmoto K, Hattori Y, Ieiri T, Niva A. Activation of macrophages by lactoferrin: Secre- tion of TNF-alpha, IL-8 and NO. Biotechnol Biochem 1997;60:521-523.